Monthly Archives: February 2022

Crohn’s disease (CD) is an immune-mediated, chronic inflammatory disease without a present cure. Surgical intervention for disease complications is common among CD patients, however post-operative strategies to prevent disease recurrence represent a cr… Continue reading →

Chronic gut inflammation such as inflammatory bowel diseases is thought as being associated with neurodegenerative diseases in humans. The direct evidence for and the underlying mechanism of this brain-gut interaction, however, remain elusive. Continue reading →

In patients with ulcerative colitis (UC), Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, data regarding the ability of EcN to increase health-related quality of life or induce remission, compared… Continue reading →

We have developed an innate immune model of colitis that occurs in the absence of adaptive immunity, is early-onset, 100% penetrant, chronic, and dependent on microbes. villin-TNFAIP3 transgenic mice, crossed to RAG1-/- mice (aka TRAG mice) develop inn… Continue reading →

Ozanimod is an oral small molecule sphingosine 1-phosphate receptor modulator approved for relapsing forms of multiple sclerosis (RMS) and moderately to severely active ulcerative colitis (UC) and under development for Crohn’s disease. Ozanimod and its… Continue reading →

Anterior gradient 2 (AGR2) is an epithelial protein disulfide isomerase critical for mucus production and endoplasmic reticulum (ER) homeostasis. Loss-of-function genetic variants in AGR2 are associated with Crohn’s disease (CD), and AGR2-deficient mic… Continue reading →

Omilancor is an oral, once-daily, gut-restricted, small molecule, first-in-class therapeutic for Crohn’s disease (CD) and ulcerative colitis (UC) that targets the novel LANCL2 pathway. Through LANCL2 activation, omilancor increases the suppressive capa… Continue reading →

Several groups have described a subset of CD8 T cells with immunosuppressive characteristics in inflammatory disease settings. The increased prevalence of a defined subset of CD8 T cells and correlation to disease has been reported in mouse and human a… Continue reading →

ABP 501 (AMGEVITA®) was the first approved biosimilar to adalimumab reference product (RP) by the European Medicines Agency and has been marketed in the European Union since 2018. Additional real-world data on its efficacy and safety, particularly for … Continue reading →

Patients with inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC) have been shown to be at up to a 40% increased risk of developing Parkinson’s disease (PD), a progressive neurodegenerative disorder. Even though a geneti… Continue reading →